The U.S. Food and Drug Administration Approves Pirtobrutinib (Jaypirca) for Relapsed/Refractory Mantle Cell Lymphoma
On January 27, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved pirtobrutinib…
Lymphoma News
The U.S. Food and Drug Administration Approves Zanubrutinib (Brukinsa) for Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL)
On January 19, the U.S. Food and Drug Administration (FDA) announced it has approved bruton tyrosine…
The U.S. Food and Drug Administration Approves Mosunetuzumab-axgb (Lunsumio) for Follicular Lymphoma
On December 22, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved…
Mobile Health Technology Helps Blood Cancer Patients Navigate Diagnosis
These days, a cellphone is much more than just a phone – it’s a photo album, a GPS, a stereo system, an encyclopedia, a computer, a gaming system, a suite of tools all in the palm of your hand. One of the many tools that can be accessed via mobile technology are apps intended to help manage your health, sometimes known as mobile health technology.
The U.S. Food and Drug Administration Approves Brentuximab Vedotin (Adcetris) for Hodgkin Lymphoma
On November 11, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved the use of brentuximab vedotin (Adcetris), for pediatric patients 2 years of age and older with previously untreated high-risk classical Hodgkin lymphoma (cHL).
U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (BREYANZI) for Large B-Cell Lymphoma
The U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma On…
U.S. Food and Drug Administration Approves CAR T Cell Therapy for Follicular Lymphoma
FDA announced it has approved the use of tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Advocating for Answers
After 20 years of living with lymphoma, Lois Rosenblum knows firsthand the importance of a strong support system and advocating
for your health. Following an initial diagnosis of follicular lymphoma in 2002 and several disease transformations since then, she’s passionate about supporting the work that the Lymphoma Research Foundation (LRF) does to power cutting-edge research to treat and defeat lymphoma.
Patient Perspectives: Dispelling Myths About Clinical Trials
Clinical trials are important for advancing research and can provide patients with access to the most cutting-edge treatments. LRF Associate Director of Support Services and Helpline specialist, Izumi Nakano, answers some common questions about clinical trials to help better understand the process and what to think about when considering enrolling in one.
U.S. Food and Drug Administration Approves CAR T Cell Therapy for Large B-Cell Lymphoma
The U.S. Food and Drug Administration Approves Axicabtagene Ciloeucel (YESCARTA) for Diffuse Large B-Cell Lymphoma…
Stay informed with news, alerts and other resources.
